Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Postoperative chemoradiotherapy is the recommended standard therapy for patients with locally advanced rectal cancer. In recent years, encouraging results with preoperative radiotherapy have been reported. We compared preoperative chemoradiotherapy with postoperative chemoradiotherapy for locally advanced rectal cancer. METHODS: We randomly assigned patients with clinical stage T3 or T4 or node-positive disease to receive either preoperative or postoperative chemoradiotherapy. The preoperative treatment consisted of 5040 cGy delivered in fractions of 180 cGy per day, five days per week, and fluorouracil, given in a 120-hour continuous intravenous infusion at a dose of 1000 mg per square meter of body-surface area per day during the first and fifth weeks of radiotherapy. Surgery was performed six weeks after the completion of chemoradiotherapy. One month after surgery, four five-day cycles of fluorouracil (500 mg per square meter per day) were given. Chemoradiotherapy was identical in the postoperative-treatment group, except for the delivery of a boost of 540 cGy. The primary end point was overall survival. RESULTS: Four hundred twenty-one patients were randomly assigned to receive preoperative chemoradiotherapy and 402 patients to receive postoperative chemoradiotherapy. The overall five-year survival rates were 76 percent and 74 percent, respectively (P=0.80). The five-year cumulative incidence of local relapse was 6 percent for patients assigned to preoperative chemoradiotherapy and 13 percent in the postoperative-treatment group (P=0.006). Grade 3 or 4 acute toxic effects occurred in 27 percent of the patients in the preoperative-treatment group, as compared with 40 percent of the patients in the postoperative-treatment group (P=0.001); the corresponding rates of long-term toxic effects were 14 percent and 24 percent, respectively (P=0.01). CONCLUSIONS: Preoperative chemoradiotherapy, as compared with postoperative chemoradiotherapy, improved local control and was associated with reduced toxicity but did not improve overall survival.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among the patients in whom abdominoperineal resection (APR) was considered necessary at the time of enrollment, the percentage of patients in whom sphincter preservation was possible was significantly higher in the preoperative chemoradiotherapy group [119].”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [119]
In the citing paper
“there was no significant difference in the 5-year survival rate”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [119]
In the citing paper
“but the local recurrence rate and incidence of grade 3 or higher adverse events were significantly lower in the preoperative chemoradiotherapy group.”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [119]
Citations
Cites
Statistical Methods in Cancer Research
Breslow, N. E. (1980) · Cited by 7,332
Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer
Kapiteijn, E., Marijnen, C. A. M., Nagtegaal, I. D., Putter, H., Steup, W. H., Wiggers, T., Rutten, H. J. T., Pahlman, L., Glimelius, B., van Krieken, J. H. J. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010580 · Cited by 4,205
Improved Survival with Preoperative Radiotherapy in Resectable Rectal Cancer
(1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361402 · Cited by 2,517
Effective Surgical Adjuvant Therapy for High-Risk Rectal Carcinoma
Krook, J. E., Moertel, C. G., Gunderson, L. L., Wieand, H. S., Collins, R. T., Beart, R. W., Kubista, T. P., Poon, M. A., Meyers, W. C., Mailliard, J. A., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103143241101 · Cited by 1,879
Statistical methods in cancer research. Vol. 1. The analysis of case-control studies
(1983) · Food and Chemical Toxicology · doi:10.1016/0278-6915(83)90281-8 · Cited by 1,716
Prolongation of the Disease-Free Interval in Surgically Treated Rectal Carcinoma
Gastrointestinal Tumor Study Group (1985) · New England Journal of Medicine · doi:10.1056/nejm198506063122301 · Cited by 1,130
(2001) · The Lancet · doi:10.1016/s0140-6736(01)06409-1 · Cited by 870
Preoperative Radiotherapy for Resectable Rectal Cancer: A Meta-analysis
Cammà, C., Giunta, M., Fiorica, F., Pagliaro, L., Craxì, A., & Cottone, M. (2000) · JAMA · doi:10.1001/jama.284.8.1008 · Cited by 754
NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer
(1990) · JAMA · doi:10.1001/jama.264.11.1444 · Cited by 394
Hyams, D. M., Mamounas, E. P., Petrelli, N., Rockette, H., Jones, J., Wieand, S. H., Deutsch, M., Wickerham, L. D., Fisher, B., & Wolmark, N. (1997) · Diseases of the Colon & Rectum · doi:10.1007/bf02054976 · Cited by 360
Research works printed but not linked: 3
- Seegenschmiedt MH, 1993, Strahlenther Onkol, 169, 83
- Pichlmaier H, 1994, Chirurg, 65, 411
- Hermanek P. What can the pathologist tell the surgeon about rectal cancer resection? In: Scholefield JH, ed. Challenges in colorectal cancer. Oxford, England: Blackwell, 2000:81-90.
Cited by
Items 301–400 of 1,004
Thompson, M. K., Poortmans, P. M., Chalmers, A. J., Finn, C. F., Hall, E., Huddart, R. A., Lievens, Y. N., Sebag‐Montefiore, D., & Coles, C. E. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0201-z · Cited by 148
Zhu, J. Y., Liu, A., Sun, X., Liu, L., Zhu, Y., Zhang, T., Jia, J., Tan, S., Wu, J., Wang, X., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01932 · Cited by 129
“Preoperative chemoradiotherapy (CRT) followed by surgery is the standard treatment of locally advanced rectal cancer.(1,2) However, the pathologic complete response (pCR) rate is only 10% to 15%, and the distant metastasis rate is .”
BackgroundKruschewski, M., Rieger, H., Pohlen, U., Hotz, H. G., & Buhr, H. J. (2007) · International Journal of Colorectal Disease · doi:10.1007/s00384-006-0260-0 · Cited by 129
“Until December 2004, neoadjuvant treatment was only administered in T4 cancers and not, as practiced today, in T3 and N+ cancers [15], which explains the apparently small number of patients (6.”
BackgroundNeoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits
Heinrich, S., & Lang, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081622 · Cited by 133
“In contrast to general concerns, these studies have demonstrated that neoadjuvant is better tolerated than adjuvant therapy, and that patients receive more treatment, if it is started preoperatively [4,5].”
ResultAgostini, M., Pucciarelli, S., Enzo, M. V., Bianco, P. D., Briarava, M., Bedin, C., Maretto, I., Friso, M. L., Lonardi, S., Mescoli, C., et al. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1638-y · Cited by 138
“The peculiar aspects of this approach are related to clinical overstaging, which may result in an unnecessary neoadjuvant treatment in almost one-fifth—18% in a German trial—of patients.(2) In addition, the disease of approximately 40% of patients shows poor or no response to preoperative CRT, while a Presented as a p…”
BackgroundMachiels, J.-P., Duck, L., Honhon, B., Coster, B. D., Coche, J.-C., Scalliet, P. G. M., Humblet, Y., Aydın, S., Kerger, J. N., Remouchamps, V. M., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi406 · Cited by 134
“Recently, the German Rectal Cancer Study Group reported that preoperative chemoradiation improved local control and was associated with reduced toxicity, but did not improve survival compared with postoperative therapy [13].”
BackgroundLahaye, M. J., Beets, G. L., Engelen, S. M. E., Kessels, A. G. H., de Bruı̈ne, A. P., Kwee, H., van Engelshoven, J. M. A., van de Velde, C. J. �., & Beets‐Tan, R. G. H. (2009) · Radiology · doi:10.1148/radiol.2521081364 · Cited by 128
Marks, J. H., Valsdóttir, E. B., DeNittis, A., Yarandi, S., Newman, D. A., Nweze, I. C., Mohiuddin, M., & Marks, G. J. (2009) · Surgical Endoscopy · doi:10.1007/s00464-009-0326-5 · Cited by 127
Yoon, S. M., Kim, D. Y., Kim, T. H., Jung, K. H., Chang, H. J., Koom, W. S., Lim, S., Choi, H. S., Jeong, S., & Park, J. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.04.047 · Cited by 129
Kerr, S., Norton, S., & Glynne‐Jones, R. (2008) · British journal of surgery · doi:10.1002/bjs.6377 · Cited by 137
Impact of a Structured Report Template on the Quality of MRI Reports for Rectal Cancer Staging
Sahni, V. A., Balthazar, P., Sainani, N. I., & Khorasani, R. (2015) · American Journal of Roentgenology · doi:10.2214/ajr.14.14053 · Cited by 138
“Neoadjuvant chemoradiotherapy has been shown in certain stages of rectal cancer (stage II or III) to reduce the frequency of local recurrence and possibly increase 5-year survival [13–16].”
BackgroundSun, W., Dou, R., Chen, J., Lai, S., Zhang, C., Ruan, L., Kang, L., Deng, Y., Lan, P., Wang, L., et al. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-07096-8 · Cited by 137
Long-Term Anorectal Dysfunction After Postoperative Radiotherapy for Rectal Cancer
Lundby, L., Krogh, K., Jensen, V. J., Gandrup, P., Qvist, N., Overgaard, J., & Laurberg, S. (2005) · Diseases of the Colon & Rectum · doi:10.1007/s10350-005-0049-1 · Cited by 126
Hatfield, P., Hingorani, M., Radhakrishna, G., Cooper, R., Melcher, A. A., Crellin, A. M., Kwok‐Williams, M., & Sebag‐Montefiore, D. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.04.007 · Cited by 134
“Pre-operative chemoradiotherapy (CRT) has been shown to be superior in terms of local control and toxicity than post-operative treatment [16].”
BackgroundSuárez, J., Vera, R., Balén, E. M., Gómez, M., Arias, F., Lera, J. M., Herrera, J. J., & Zazpe, C. (2007) · Colorectal Disease · doi:10.1111/j.1463-1318.2007.01424.x · Cited by 125
Association of Plane of Total Mesorectal Excision With Prognosis of Rectal Cancer
Kitz, J., Fokas, E., Beißbarth, T., Ströbel, P., Wittekind, C., Hartmann, A., Rüschoff, J., Papadopoulos, T., Rösler, E., Ortloff-Kittredge, P., et al. (2018) · JAMA Surgery · doi:10.1001/jamasurg.2018.1607 · Cited by 125
Self-citationPerez, R. O., Habr‐Gama, A., Gama-Rodrigues, J. J., Proscurshim, I., Julião, G. P. S., Lynn, P. B., Ono, C. R., Campos, F. G., Sousa, A. H. S. E., Imperiale, A. R., et al. (2011) · Cancer · doi:10.1002/cncr.26644 · Cited by 126
“INTRODUCTION Multimodality therapy has been considered the preferred initial treatment strategy for patients with locally advanced rectal cancer.(1,2) It has been demonstrated that neoadjuvant chemoradiation (CRT) improves local disease control after radical surgery.”
BackgroundLaparoscopic Resection for Rectal Cancer: A Review
Poon, J. T. C., & Law, W. L. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0603-5 · Cited by 123
Smith, F. M., Reynolds, J. V., Miller, N., Stephens, R. B., & Kennedy, M. J. (2005) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2005.09.010 · Cited by 125
Perez, R. O., Julião, G. P. S., Habr‐Gama, A., Kiss, D. R., Proscurshim, I., Campos, F. G., Gama-Rodrigues, J. J., & Cecconello, I. (2009) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e31819ef76b · Cited by 123
Jung, S. H., Heo, S. H., Kim, J. W., Jeong, Y. Y., Shin, S. S., Soung, M., Kim, H. R., & Kang, H. K. (2011) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.22749 · Cited by 131
“Neoadjuvant CRT has been shown to allow downsizing and downstaging of the tumor, thus leading to improved resectability and local control (4,5).”
BackgroundNonoperative Approaches to Rectal Cancer: A Critical Evaluation
Habr‐Gama, A., Perez, R. O., Julião, G. P. S., Proscurshim, I., & Gama-Rodrigues, J. J. (2011) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2011.02.010 · Cited by 132
Non-operative management of rectal cancer after neoadjuvant chemoradiation
Habr‐Gama, A., & Perez, R. O. (2009) · British journal of surgery · doi:10.1002/bjs.6470 · Cited by 123
Kitayama, J., Yasuda, K., Kawai, K., Sunami, E., & Nagawa, H. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-64 · Cited by 124
“Recently, addition of chemotherapy to RT (CRT) has achieved even more favorable results [1-3], and preoperative RT in the neoadjuvant setting is thus currently recognized as the standard treatment for locally advanced RC.”
BackgroundTumor Budding in Colorectal Carcinoma
Graham, R. P., Vierkant, R. A., Tillmans, L. S., Wang, A. H., Laird, P. W., Weisenberger, D. J., Lynch, C. F., French, A. J., Slager, S. L., Raissian, Y., et al. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000504 · Cited by 122
CEA – A Predictor for Pathologic Complete Response After Neoadjuvant Therapy for Rectal Cancer
Wallin, U., Rothenberger, D. A., Lowry, A. C., Luepker, R. V., & Mellgren, A. F. (2013) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e31828e5a72 · Cited by 121
Ryan, D. P., Niedzwiecki, D., Hollis, D. R., Mediema, B. E., Wadler, S., Tepper, J. E., Goldberg, R. M., & Mayer, R. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.6754 · Cited by 121
“control and less toxicity when compared with postoperative chemoradiotherapy.(6)”
BackgroundMethodInfluentialCreavin, B., Ryan, É. J., Martin, S., Hanly, A. M., O’Connell, P. R., Sheahan, K. D., & Winter, D. C. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.417 · Cited by 132
Hong, T. S., Moughan, J., Garofalo, M. C., Bendell, J. C., Berger, A. C., Oldenburg, N. B. E., Anne, P. R., Perera, F. E., Lee, R. J., Jabbour, S. K., et al. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.05.005 · Cited by 127
Neoadjuvant Therapy in Rectal Cancer
Fleming, F. J., Påhlman, L., & Monson, J. R. T. (2011) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e31820eeb37 · Cited by 130
“This approach typically also involves the administration of concurrent infusional 5-fluorouracil-based chemotherapy.(13,24,25) The rationale for giving chemotherapy concurrently with radiotherapy is that it potentiates local radiotherapy sensitization and has the potential to induce tumor downsizing and/or downstaging…”
BackgroundMethodResultInfluentialGarland, M. L., Vather, R., Bunkley, N., Pearse, M., & Bissett, I. P. (2014) · International Journal of Colorectal Disease · doi:10.1007/s00384-013-1821-7 · Cited by 128
“Additionally, it is postulated to enhance long-term oncologic outcomes by eliminating early metastatic cancer cells in local lymphatics [6].”
BackgroundHuang, M., Liang, J., Wang, H., Kang, L., Deng, Y., & Wang, J. (2010) · International Journal of Colorectal Disease · doi:10.1007/s00384-010-1091-6 · Cited by 120
“Neoadjuvant therapy such as preoperative chemoradiotherapy can decrease local recurrence rates in resectable rectal cancer compared with surgery alone [35].”
BackgroundInfluentialRestaging of Rectal Cancer with MR Imaging after Concurrent Chemotherapy and Radiation Therapy
Kim, D. J., Kim, J. H., Lim, J. S., Yu, J., Chung, J. B., Kim, M., & Kim, K. W. (2010) · Radiographics · doi:10.1148/rg.302095046 · Cited by 120
Kunkler, I. H., Audisio, R. A., Belkacémi, Y., Betz, M., Gore, E., Hoffe, S. E., Kirova, Y., Koper, P. C. M., Lagrange, J., Markouizou, A., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu104 · Cited by 127
Perez, R. O., Habr‐Gama, A., Lynn, P. B., Julião, G. P. S., Bianchi, R., Proscurshim, I., & Gama-Rodrigues, J. J. (2012) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e318273f56f · Cited by 133
Kennedy, E. D., Simunovic, M. R. I., Jhaveri, K. S., Kirsch, R., Brierley, J., Drolet, S., Brown, C. J., Vos, P. M., Xiong, W., MacLean, T., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0186 · Cited by 128
Quah, H. M., Samad, A., Neathey, A. J., Hay, D. J., & Maw, A. (2005) · Colorectal Disease · doi:10.1111/j.1463-1318.2005.00884.x · Cited by 120
Gastric cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Jackson, C., Cunningham, D., & Oliveira, J. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp122 · Cited by 125
Herrle, F., Șandra-Petrescu, F., Weiß, C., Post, S., Runkel, N., & Kienle, P. (2016) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000000545 · Cited by 119
Management of Recurrent Rectal Cancer
Bouchard, P., & Efron, J. E. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0861-2 · Cited by 122
“Similarly, randomized controlled trials have demonstrated that the use of both neoadjuvant and adjuvant therapy decreases local recurrence, while neoadjuvant therapy may decrease late toxicity and increase sphincter preservation.(3,4) Locally recurrent rectal cancer has devastating consequences such as disabling pain…”
BackgroundDiverting Stoma After Low Anterior Resection: More Arguments in Favor
Ulrich, A. B., Seiler, C. M., Rahbari, N. N., Weitz, J., & Büchler, M. W. (2009) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e318197e1b1 · Cited by 119
Optimal Surgery Time After Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancers
Lim, S., Choi, H. S., Jeong, S., Kim, D. Y., Jung, K. H., Hong, Y. S., Chang, H. J., & Park, J. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e31817fc2a0 · Cited by 123
“During the same study period, 16 patients underwent surgery more than 8 weeks following the end of CRT.”
BackgroundInfluentialDas, P., Delclos, M. E., Skibber, J. M., Rodríguez-Bigas, M. A., Feig, B. W., Chang, G. J., Eng, C., Bedi, M., Krishnan, S., & Crane, C. H. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.04.056 · Cited by 119
“5) Indication for retreatment Recurrent rectal cancer 48 (96) Primary rectal cancer 2 (4) Retreatment dose 39 Gy 47 (94) 30 Gy 3 (6) Patient characteristics”
BackgroundKhrizman, P., Niland, J. C., ter Veer, A., Milne, D. E., Dunn, K. B., Carson, W. E., Engstrom, P. F., Shibata, S., Skibber, J. M., Weiser, M. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.3188 · Cited by 125
“Although decreased local recurrence rates for patients with stage II/III rectal cancer have been achieved with the use of combination chemotherapy and radiation therapy, 35% of patients nevertheless develop metastatic disease.(2,20) Current NCCN CRC Guidelines recommend completion of a 6-month course of adjuvant chemo…”
Diffusion‐weighted Magnetic Resonance Imaging for Detecting Lymph Node Metastasis of Rectal Cancer
Mizukami, Y., Ueda, S., Mizumoto, A., Sasada, T., Okumura, R., Kohno, S., & Takabayashi, A. (2011) · World Journal of Surgery · doi:10.1007/s00268-011-0986-x · Cited by 127
“Recently, several studies have reported the beneficial effects of neoadjuvant chemoradiotherapy in terms of a reduced local recurrence rate [16, 17], and neoadjuvant chemoradiotherapy before rectal resection with TME has been widely accepted as the standard treatment for locally advanced rectal cancer.”
BackgroundInfluence of Preoperative Chemoradiotherapy on the Number of Lymph Nodes Retrieved in Rectal Cancer
Ha, Y. H., Jeong, S., Lim, S., Choi, H. S., Hong, Y. S., Chang, H. J., Kim, D. Y., Jung, K. H., & Park, J.-G. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181e61e33 · Cited by 118
“For locally advanced rectal cancer, preoperative chemoradiotherapy has become a standard component of multimodal treatment because of its oncologic benefits over surgery alone(2) and postoperative chemoradiotherapy.(3) Preoperative radiotherapy is traditionally considered to decrease the number of analyzable lymph nod…”
BackgroundSong, I., Kim, S. H., Lee, S. J., Choi, J. Y., Kim, M. J., & Rhim, H. (2012) · British Journal of Radiology · doi:10.1259/bjr/68424021 · Cited by 117
“In previous randomised studies [39, 40], 8–15% of patients who underwent neoadjuvant CRT showed complete response.”
BackgroundKim, J. C., Kim, T. W., Kim, J. H., Yu, C. S., Kim, H. C., Chang, H. M., Ryu, M. H., Park, J., Ahn, S. D., Lee, S.-W., et al. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.02.046 · Cited by 118
Huh, J. W., Kim, H. R., & Kim, Y. J. (2013) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e3182837e5b · Cited by 117
Duldulao, M. P., Lee, W., Streja, L., Chu, P. G., Li, W., Chen, Z., Kim, J., & García‐Aguilar, J. (2013) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e31827541e2 · Cited by 116
Modern management of rectal cancer: A 2006 update
Balch, G. C. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i20.3186 · Cited by 115
Krishnan, S., Janjan, N. A., Skibber, J. M., Rodríguez-Bigas, M. A., Wolff, R. A., Das, P., Delclos, M. E., Chang, G. J., Hoff, P. M., Eng, C., et al. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.05.063 · Cited by 116
Findlay, V. J., Wang, C., Watson, D. K., & Camp, E. R. (2014) · Cancer Gene Therapy · doi:10.1038/cgt.2014.15 · Cited by 114
Pathologic Complete Response in Rectal Cancer
Nahas, S. C., Nahas, C. S. R., Marques, C. F. S., Ribeiro, U., Cotti, G. C. D. C., Imperiale, A. R., Capareli, F. C., Chen, A. T. C., Hoff, P. M., & Cecconello, I. (2016) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000000558 · Cited by 115
Neoadjuvant chemotherapy in locally advanced colon cancer: a systematic review and meta-analysis
Gosavi, R., Chia, C., Michael, M., Heriot, A. G., Warrier, S. K., & Kong, J. C. H. (2021) · International Journal of Colorectal Disease · doi:10.1007/s00384-021-03945-3 · Cited by 114
“However, use of neoadjuvant treatment is not without risk: it has been associated with chemotoxicity resulting in delay to surgery, disease progression, risk of bowel obstruction or perforation requiring emergency surgery [6, 7, 10].”
BackgroundThe ‘good’, the ‘bad’, and the ‘ugly’ rectal cancers
Blomqvist, L., & Glimelius, B. L. G. (2007) · Acta Oncologica · doi:10.1080/02841860701802585 · Cited by 123
“[25] Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al.”
BackgroundSignificance of Acellular Mucin Pools in Rectal Carcinoma After Neoadjuvant Chemoradiotherapy
Shia, J., McManus, M. C., Guillem, J. G., Leibold, T., Zhou, Q. C., Tang, L. H., Riedel, E., Weiser, M. R., Paty, P. B., Temple, L. K. F., et al. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318200cf78 · Cited by 113
Andrès, A., Toso, C., Adam, R. A., Barroso, E., Hubert, C., Capussotti, L., Gerstel, E., Roth, A. D., Majno, P. E., & Mentha, G. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e3182734423 · Cited by 119
Araújo, R. O., Valadão, M., Borges, D., Linhares, E., de Jesus, J. P., Ferreira, C. G., Victorino, A. P., Vieira, F. M. D. A. C., & Albagli, R. D. O. (2015) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2015.08.156 · Cited by 121
Tsukamoto, S., Fujita, S., Ota, M., Mizusawa, J., Shida, D., Kanemitsu, Y., Ito, M., Shiomi, A., Komori, K., Ohue, M., et al. (2020) · British journal of surgery · doi:10.1002/bjs.11513 · Cited by 113
Rovers, K. P. B., Bakkers, C., Simkens, G. A. A. M., Burger, J. W. A., Nienhuijs, S. W., Creemers, G., Thijs, A. M. J., Brandt‐Kerkhof, A. R. M., Madsen, E. V. E., Ayez, N., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5545-0 · Cited by 119
Intven, M., van Otterloo, S. R. D. M., Mook, S., Doornaert, P., Breugel, E. N. D. G.-V., Sikkes, G. G., Willemsen-Bosman, M. E., van Zijp, H. M., & Tijssen, R. H. N. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.09.024 · Cited by 111
Maurer, C. A., Renzulli, P., Kull, C., Käser, S. A., Mazzucchelli, L., Ulrich, A. B., & Büchler, M. W. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1571-0 · Cited by 123
Maas, M., Nelemans, P. J., Valentini, V., Crane, C. H., Capirci, C., Rödel, C. M., Nash, G. M., Kuo, L., Glynne‐Jones, R., García‐Aguilar, J., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29355 · Cited by 112
Self-citationSchou, J. V., Larsen, F. O., Rasch, L., Linnemann, D., Langhoff, J. L., Høgdall, E. V. S., Nielsen, D. L., Vistisen, K. K., Fromm, A., & Jensen, B. V. (2012) · Annals of Oncology · doi:10.1093/annonc/mds056 · Cited by 121
“Preoperative chemoradiation for rectal cancer has been shown to improve local control [18] but single studies with 5-FUbased preoperative CRT did not improve DFS and OS and had no impact on distant metastases [13, 14].”
BackgroundWieder, H. A., Geinitz, H., Rosenberg, R., Lordick, F., Becker, K., Stahl, A. R., Rummeny, E. J., Siewert, J. R., Schwaiger, M., & Stollfuß, J. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0292-2 · Cited by 110
“In patients with locally advanced (T3/T4) tumours, neoadjuvant chemoradiotherapy has become the standard of care in many countries because it has been shown that preoperative chemoradiation leads to a higher rate of sphincter-preserving surgical resection as well as improved local control compared with adjuvant (posto…”
BackgroundCapecitabine in the management of colorectal cancer
Zafar, S. Y., & Hirsch (2011) · Cancer Management and Research · doi:10.2147/cmar.s11250 · Cited by 105
the OCUM group, Ruppert, R., Junginger, T., Ptok, H., Straßburg, J., Maurer, C. A., Brosi, P., Sauer, J., Baral, J., Kreis, M. E., et al. (2018) · British journal of surgery · doi:10.1002/bjs.10879 · Cited by 114
Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
Janssen, Q. P., O'Reilly, E. M., van Eijck, C. H. J., & Koerkamp, B. G. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00041 · Cited by 139
Wiltshire, K. L., Ward, I., Swallow, C. J., Oza, A. M., Cummings, B., Pond, G. R., Catton, P. A., Kim, J., Ringash, J. G., Wong, C. S., et al. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.08.012 · Cited by 110
Bujko, K., Kępka, L., Michalski, W., & Nowacki, M. P. (2006) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2006.04.012 · Cited by 120
“004) in the ARs rate in the experimental arm in the subgroup of patents for whom APR was deemed necessary before randomisation [46].”
BackgroundMethodResultInfluentialHorisberger, K., Treschl, A., Mai, S., Miranda, M. B., Kienle, P., Ströbel, P., Erben, P., Woernle, C. M., Dinter, D. J., Kähler, G. F. B. A., et al. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.10.014 · Cited by 110
Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer
Frasson, M., García‐Granero, E., Roda, D., Lorente, B. F., Roselló, S., Esclápez, P., Faus, C., Navarro, S., Campos, S., & Cervantes, A. M. R. (2011) · Cancer · doi:10.1002/cncr.25866 · Cited by 116
“Neoadjuvant CRT, as an alternative option, produces better local control and less acute and chronic toxicity compared with postoperative treatment.(3) However, 2 important concepts have been phased into clinical practice in the last 20 years.”
BackgroundSmith, F. M., Rao, C., Perez, R. O., Bujko, K., Athanasiou, T., Habr‐Gama, A., & Faiz, O. D. (2015) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000000281 · Cited by 108
Mechera, R., Schuster, T., Rosenberg, R., & Speich, B. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.031 · Cited by 121
“92 While neoadjuvant CRT and radiotherapy (RT) only has been shown to induce 93 shrinkage of the tumour and improved local control [18-20], several studies 94 demonstrated a decrease of the number of lymph nodes examined in these pre95 treated mesorectal specimens [21-26].”
BackgroundMethodGlynne‐Jones, R., Grainger, J., Harrison, M., Ostler, P. J., & Makris, A. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602960 · Cited by 115
“Local recurrence, acute and late toxicity were all statistically significantly reduced with the preoperative approach (Sauer et al, 2004).”
BackgroundEvidence and research in rectal cancer
Valentini, V., Beets‐Tan, R. G. H., Borràs, J. M., Krivokapić, Z., Leer, J. W. H., Påhlman, L., Rödel, C. M., Schmoll, H., Scott, N., de Velde, C. V., et al. (2008) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2008.05.022 · Cited by 120
Self-citationBertolini, F., Bengala, C., Losi, L., Pagano, M., Iachetta, F., Dealis, C., Jovic, G., Depenni, R., Zironi, S., Falchi, A., et al. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.02.018 · Cited by 107
Fietkau, R., Barten, M., Klautke, G., Klar, E., Ludwig, K., Thomas, H., Brinckmann, W., Friedrich, K. A., Prall, F., Hartung, G., et al. (2006) · Diseases of the Colon & Rectum · doi:10.1007/s10350-006-0570-x · Cited by 107
Self-citationOptimizing the outcome of surgery in patients with rectal cancer and synchronous liver metastases
van der Pool, A. E., de Wilt, J. H. W., Lalmahomed, Z. S., Eggermont, A. M. M., IJzermans, J. N. M., & Verhoef, C. K. (2010) · British journal of surgery · doi:10.1002/bjs.6947 · Cited by 109
Belluco, C., Paoli, A. D., Canzonieri, V., Sigon, R., Fornasarig, M., Buonadonna, A., Boz, G., Innocente, R., Perin, T., Cossaro, M., et al. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1822-0 · Cited by 113
Latkauskas, T., Paužas, H., Gineikienė, I., Jančiauskienė, R., Juozaitytė, E., Saladžinskas, Ž., Tamelis, A., & Pavalkis, D. (2011) · Colorectal Disease · doi:10.1111/j.1463-1318.2011.02815.x · Cited by 108
Heinrich, S., Pestalozzi, B., Lesurtel, M., Berrevoet, F., Laurent, S., Delpero, J.-R., Raoul, J.-L., Bachellier, P., Dufour, P., Moehler, M., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-346 · Cited by 106
“Neoadjuvant treatments are established concepts for rectal and gastric cancer [18,19], where the toxicity is better tolerated [19].”
Kim, I. Y., You, S. H., & Kim, Y. W. (2014) · BMC Surgery · doi:10.1186/1471-2482-14-94 · Cited by 112
Locally advanced rectal cancer: The past, present, and future
Oronsky, B. T., Reid, T. R., Larson, C., & Knox, S. J. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.02.001 · Cited by 120
Long-Term Survival and Recurrence Outcomes Following Surgery for Distal Rectal Cancer
Silberfein, E. J., Kattepogu, K., Hu, C., Skibber, J. M., Rodríguez-Bigas, M. A., Feig, B. W., Das, P., Krishnan, S., Crane, C. H., Kopetz, S., et al. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1119-8 · Cited by 109
“In addition to surgery, combined chemoradiation therapy (CRT) is recommended for patients with stage II or stage III disease to improve local control and overall survival.(2,3) Despite these improvements, treatment of distal rectal cancer remains clinically challenging in terms of both the suitability of performing sp…”
Maffione, A. M., Marzola, M. C., Capirci, C., Colletti, P. M., & Rubello, D. (2015) · American Journal of Roentgenology · doi:10.2214/ajr.14.13210 · Cited by 107
Cheung, W. Y., Neville, B. A., & Earle, C. C. (2009) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e3181a51173 · Cited by 104
Mawdsley, S., Glynne‐Jones, R., Grainger, J., Richman, P. I., Makris, A., Harrison, M., Ashford, R., Harrison, R., Osborne, M., Livingstone, J. I., et al. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.03.003 · Cited by 107
Jakobsen, A. K. M., Pløen, J., Vuong, T., Appelt, A. L., Lindebjerg, J., & Rafaelsen, S. R. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.02.006 · Cited by 112
Callender, G. G., Das, P., Rodríguez-Bigas, M. A., Skibber, J. M., Crane, C. H., Krishnan, S., Delclos, M. E., & Feig, B. W. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0735-7 · Cited by 110
“However, preoperative CXRT has become the standard of care in the United States because it is associated with reduced acute and chronic toxicity rates, improved local control, and increased sphincter-preservation rates.(6,7) Surgery for rectal cancer includes proctectomy via low”
BackgroundTotal Neoadjuvant Therapy: A Shifting Paradigm in Locally Advanced Rectal Cancer Management
Franke, A. J., Parekh, H. D., Starr, J. S., Tan, S., Iqbal, A., & George, T. J. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.06.008 · Cited by 108
“nical Colorectal Cancer March 2018 statistically powered to evaluate the optimal timing of CTX and RT relative to surgery.(5,6) The benefits of CRT for LARC were originally described in the postoperative period, where 2 landmark trials demonstrated that adjuvant CRT significantly decreased LRR compared with observatio…”
MethodExpression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors
Xie, S., Huang, J., Qiao, Q., Zang, W., Hong, S., Tan, H., Dong, C., Yang, Z., & Ni, L. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2227-8 · Cited by 105
Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer
Kamran, S. C., Lennerz, J. K., Margolis, C. A., Liu, D., Reardon, B. M., Wankowicz, S. A. M., Seventer, E. E. V., Tracy, A. A., Wo, J. Y.-L., Carter, S. L., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0908 · Cited by 116
“4 Gy radiotherapy, followed by surgical resection within 8–11 weeks between 2010 and 2016 (20).”
MethodWelton, M. L., Shelton, A. A., Chang, G. J., & Varma, M. G. (2008) · Springer eBooks · doi:10.1007/978-0-387-68113-9_52 · Cited by 106
Willeke, F., Horisberger, K., Kraus-Tiefenbacher, U., Wenz, F. K., Leitner, A., Hochhaus, A., Grobholz, R., Willer, A., Kähler, G. F. B. A., Post, S., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603645 · Cited by 114
“It could be demonstrated that (i) the best way to deliver radiotherapy is neoadjuvant (CAO/AIO-ARO-94 trial (Sauer et al, 2004; MRC CR07 – Sebag-Montefiore et al, 2006), (ii) adding 5-FU to neoadjuvant radiotherapy improves the pCR and the local recurrence rates albeit by the price of higher acute…”
Toxicity and complications of preoperative chemoradiotherapy for locally advanced rectal cancer
Swellengrebel, H. A. M., Marijnen, C. A. M., Verwaal, V. J., Vincent, A. D., Heuff, G., Gerhards, M. F., van Geloven, A. A. W., van Tets, W. F., Verheij, M., & Cats, A. (2010) · British journal of surgery · doi:10.1002/bjs.7315 · Cited by 120
Ansari, N., Solomon, M. J., Fisher, R., Mackay, J., Burmeister, B. H., Ackland, S. P., Heriot, A. G., Joseph, D. J., McLachlan, S., McClure, B., et al. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001987 · Cited by 120
Dinapoli, N., Barbaro, B., Gatta, R., Chiloiro, G., Casà, C., Masciocchi, C., Damiani, A., Boldrini, L., Gambacorta, M. A., Dezio, M., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.04.065 · Cited by 110
“Another important aspect in LARC treatment is the use of preoperative CRT, nowadays considered the standard for reducing the probability to address patients to abdominal-perineal resection and for increasing local control (11, 12).”
BackgroundPhan, K. H., Oh, L. J., Ctercteko, G. C., Pathma‐Nathan, N., Khoury, T. E., Azam, H., Wright, D. B., & Toh, J. W. T. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.11.07 · Cited by 107
Metadata
- Authors
- Sauer, R., Becker, H., Hohenberger, W., Rödel, C., Wittekind, C., Fietkau, R., Martus, P., Tschmelitsch, J., Hager, E., Hess, C. F., Karstens, J.-H., Liersch, T., Schmidberger, H., & Raab, R.
- Affiliations
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Leipzig University (DE)
- University of Rostock (DE)
- Charité – Universitätsmedizin Berlin (DE)
- Hospital of the Brothers of St. John of God (AT)
- Klinikum Klagenfurt (AT)
- University of Göttingen (DE)
- Medizinische Hochschule Hannover (DE)
- Klinikum Oldenburg (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-10-21
- Volume
- 351
- Issue
- 17
- Pages
- 1731-1740
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2125452425
- Cited by
- 6,050
- References
- 19
- Citations by year
- 2026: 178 · 2025: 205 · 2024: 232 · 2023: 275 · 2022: 310 · 2021: 324 · 2020: 322 · 2019: 321 · 2018: 305 · 2017: 298 · 2016: 291 · 2015: 348 · 2014: 340 · 2013: 333 · 2012: 346
- FWCI
- 82.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- GRO (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Surgery › Colorectal and Anal Carcinomas
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Keywords
- rectal cancer, locally advanced rectal cancer, neoadjuvant chemoradiotherapy, postoperative chemoradiotherapy, neoadjuvant therapy, adjuvant therapy, 5-fluorouracil, boost radiotherapy, local recurrence, overall survival, treatment toxicity
- MeSH terms
- Adult, Aged, Antineoplastic Agents, Combined Modality Therapy, Female, Fluorouracil, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Postoperative Care, Postoperative Complications, Preoperative Care, Quality Control, Radiotherapy, Rectal Neoplasms, Incidence, Proportional Hazards Models, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.